more

Keryx Biopharmaceuticals, Inc. (KERX)

(Delayed Data from NSDQ)

$3.36 USD

0.00 (0.00%)

Updated Dec 12, 2018 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are Options Traders Betting on a Big Move in Keryx (KERX) Stock?

by Zacks Equity Research Published on November 27,2017

Investors in Keryx (KERX) need to pay close attention to the stock based on moves in the options market lately.

KERXNo Net Change

Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines

by Zacks Equity Research Published on November 08,2017

Keryx (KERX) posted wider-than-expected loss in the third quarter of 2017. The company also received approval for label expansion of its lead drug Auryxia.

Keryx (KERX) Posts Wider Q3 Loss, Lags Sales, Shares Down

by Zacks Equity Research Published on November 07,2017

Keryx???s third-quarter 2017 loss was wider-than-expected. The company posted a loss of 20 cents per share wider than consensus estimate of a loss of 17 cents.

KERXNo Net Change

Keryx Biopharmaceuticals (KERX) in Focus: Stock Moves 10.8% Higher

by Zacks Equity Research Published on November 06,2017

Keryx Biopharmaceuticals (KERX) was a big mover last session, as the company saw its shares nearly 11% on the day amid huge volumes.

The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical

by Zacks Equity Research Published on November 06,2017

The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical

Key Predictions for Q3 Earnings Reports of MYL, HZNP & KERX

by Zacks Equity Research Published on November 03,2017

The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if generic maker Mylan and other small companies follow suit.

What to Expect from Keryx (KERX) This Earnings Season?

by Zacks Equity Research Published on October 31,2017

Keryx (KERX) will focus on the label expansion of its only approved drug, Auryxia, during the third-quarter 2017 earnings call.

Keryx Focuses on Kidney Drug Auryxia Despite Generic Threat

by Zacks Equity Research Published on September 29,2017

Keryx (KERX) is working on expanding its only marketed product, Auryxia's label.

Here's Why These 3 Biotech Stocks Might Stop Rallying (Revised)

by Zacks Equity Research Published on September 25,2017

The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.

Here's Why These 3 Biotech Stocks Might Stop Rallying

by Zacks Equity Research Published on September 20,2017

The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.

Keryx Biopharmaceuticals, Inc. (KERX) Catches Eye: Stock Jumps 5.9%

by Zacks Equity Research Published on September 18,2017

Keryx Biopharmaceuticals, Inc. (KERX) was a big mover last session, as the company saw its shares rise nearly 6% on the day

Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat

by Zacks Equity Research Published on July 28,2017

Keryx's (KERX) loss in Q2 was wider than expected but sales beat estimates. The company also raised its 2017 outlook for net U.S. Auryxia product sales.

Keryx (KERX) Posts Wider-than-Expected Q2 Loss, Sales Beat

by Zacks Equity Research Published on July 27,2017

Keryx???s second-quarter 2017 loss was wider-than-expected but it surpassed sales expectations.

KERXNo Net Change

What to Expect from Keryx (KERX) this Earnings Season?

by Zacks Equity Research Published on July 21,2017

Keryx Biopharmaceuticals, Inc. (KERX) intends to focus on the growth of Auryxia in the U.S. dialysis market. The company is also making efforts for label expansion on Auryxia in the iron-deficiency anemia (IDA) indication.